what do we do

enabling drug discovery in the ubiquitin field since 2010

Access to well-defined and advanced ubiquitin and ubiquitin-like reagents, which could so far not be routinely produced (bio)chemically, is of paramount importance for drug development, as well as for fundamental research and structural studies. Since we founded our company in 2010, it has been well recognised by both Pharma and Academia that our products enable research in the rapidly expanding ubiquitin field. Most of the leading laboratories in the field worldwide make use of our innovative catalogue and custom reagents. We also collaborate with some outstanding scientists on research projects to further our insights in this exciting field. We are proud that our joint efforts regularly result in publications in high-ranking journals. You can find examples in the section "recent publications" below on this page. For an extensive reference list of our publications since 2010, please visit our download center.

Find out about how our reagents expedite the three stages of early drug discovery (i.e. target - lead - lead on target), by clicking on the buttons below:

target

Identify and validate your target using UbiQ Probes.

lead

Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.  

lead on target

Our reagents enable you in lead on target validation and lead optimization.

target

Identify and validate your target using UbiQ Probes.

lead

Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.  

lead on target

Our reagents enable you in lead on target validation and lead optimization.

about our products

reagents

UbiQ develops, manufactures and commercializes ubiquitinated peptides, ubiquitin-based reagents and high throughput assays in our own laboratory at the Amsterdam Science Park. Next to ubiquitin, we also make ubiquitin-like variants (SUMO, ISG15, NEDD8, etc) of our reagents.  Important to note is that all our products are "For laboratory research use only, not for use in humans". 

about our services

custom made reagents

With our UbiQ technologies we are able to fully synthesize site-selective ubiquitinated peptides of native conformation, using automated solid phase peptide synthesis. This enables us to synthesize any custom made peptides.

news

our blog

Reagents for your SARS-CoV-2 research

  Reagents for your SARS-CoV-2 research  The SARS-CoV-2 coronavirus encodes a papain-like cysteine protease PLpro (NSP3) that cleaves the viral polyprotein, removes ubiquitin-like ISG15 protein modifications and (with lower activity) Lys48-linked polyubiquitin chains. As PLPro is essential for SARS-CoV-2 replication, it represents a promising target for the...

Public-private partnership grant by Health-Holland: New drug therapies by a better understanding of ubiquitin metalloprotease activity Tools to study ubiquitin metalloprotease activity.

    17 December 2019 Public-private partnership grant awarded by Health-Holland   We are happy to announce that UbiQ and Prof Titia Sixma (Netherlands Cancer Institute, Netherlands) were recently awarded a public-private partnership grant...

where to meet us

recent publications

Collaborative research between the University of York, University of Glasgow and UbiQ looks into the (essential) roles of ubiquitin proteases (DUBs) and ubiquitin conjugation in Leishmania parasites.

21st Royal Society of Chemistry - Medicinal Chemistry Symposium, 13 - 15 September 2021, Cambridge UK. Poster title: A ubiquitin activating enzyme as a novel therapeutic target for leishmaniasis. Daniel Harris (1), Dr Mads Gabrielson (2), Dr...